Complete Histologic Remission after Sunitinib Neoadjuvant Therapy in T3b Renal Cell Carcinoma
نویسندگان
چکیده
Grégoire Robert *, Grégoire Gabbay , Raphaël Bram, Hervé Wallerand , Colette Deminière , François Cornelis , Jean-Christophe Bernhard , Alain Ravaud , Philippe Ballanger a,e Bordeaux University Hospital, Department of Urology, Bordeaux, France Bordeaux University Hospital, Department of Pathology, Bordeaux, France Bordeaux University Hospital, Department of Radiology, Bordeaux, France Bordeaux University Hospital, Department of Medical Oncology, Bordeaux, France University Bordeaux 2, Victor Segalen, Bordeaux, France e u r o p e a n u r o l o g y 5 5 ( 2 0 0 9 ) 1 4 7 7 – 1 4 8 0
منابع مشابه
Modified Schedule Sunitinib in Metastatic Renal Cell Carcinoma
Background: New targeted therapies have revolutionized the treatment landscape of metastatic renal cell carcinoma over the last decade. Sunitinib has demonstrated high activity in renal cell carcinoma (RCC), still complete remission is not a common occurrence in patients. In patient achieving complete response, continuation of therapy beyond complete response is debatable. Cytoreductive nephrec...
متن کاملSunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
Renal cell carcinoma (RCC) is the most common renal cancer, and has a poor prognosis in individuals with metastases (mRCC). In this report, we describe a 48-year-old woman with unresectable multiple liver metastases and a colonic metastasis of RCC who was treated with sunitinib in combination with hepatic microwave ablation and obtained a clinical and pathological complete remission. We conside...
متن کاملPerforming cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.
OBJECTIVE To describe for surgeons contemplating performing cytoreductive nephrectomy (CRN) on patients after neoadjuvant sunitinib compared to a benchmark of open radical nephrectomy, describing technical difficulties, safety and feasibility. PATIENTS AND METHODS We compared measurable surgical parameters and perioperative complications in 22 patients with metastatic renal cell carcinoma (mR...
متن کاملDiscontinuation of the tyrosine kinase inhibitor sunitinib in patients with metastatic renal cell carcinoma: a case series.
PURPOSE Tyrosine kinase inhibitors (TKI) play a pivotal role in the modern treatment of patients with metastatic renal cell carcinoma (mRCC). Depending on the course and the response, the targeted therapy may last for years. Thus the question arises, if a successful treatment leading to a complete response or at least a stable disease after a partial remission, may be discontinued. MATERIALS ...
متن کاملClinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
We report a patient with metastatic clear-cell renal cell carcinoma (mRCC) who presented with primary tumor in situ in the left kidney and metastases to bone, liver, lungs, and brain. After over 5 years of sunitinib therapy and subsequent cytoreductive left nephrectomy, the patient achieved radiographic complete response (CR) and had pathologic CR in the nephrectomy specimen. Durable clinical a...
متن کامل